OBR Daily Commentary

forumImage

Trajectories of Injectable Cancer Drug Costs After Launch in the United States

(Journal of Clinical Oncology) October 10, 2017 - Cancer drug prices at launch have increased in recent years. It is unclear how individual drug prices change over time after launch and what market determinants influence these changes.

Winston Wong, PharmD (Posted: October 19, 2017)

quotesThis study is very similar to the study completed by Peter Bach in 2015. Dr Bach looked at the initial cost of the drug when released, and then tracked cost increases. This study confirms his finding. No matter how you slice and dice the data, the bottom line is that we are still an a time of unsustainable cost increases. The next step is to compare the increases in the US vs. Europe.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

U.S. FDA Approves Gilead Cancer Gene Therapy; Price Set At $373,000

(Reuters) Oct 18, 2017 - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc’s Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.

Sasi (Posted: October 19, 2017)

quotesWho can afford this drug?quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Exercise Interventions In Advanced Lung Cancer Patients Led To Increased Functionality, Which May Be Linked To Quality Of Life Benefits

(WCLC) Oct 18, 2017 - Physical exercise and psycho-social interventions in patients with advanced stage lung cancer improved functional capacity, which may be linked to quality of life benefits.

Dean Gesme, MD (Posted: October 18, 2017)

quotesRehabilitation and Pre-habilitation are woefully underutilized by oncologists as adjuncts to the treatments which we prescribe. Patients deserve the opportunity to optimize their physical wellbeing in order to maximize quality of life and minimize treatment related toxicities.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...